OMass Therapeutics

OMass Therapeutics is a biotechnology company based in Oxford, UK, dedicated to discovering and developing novel small molecule drugs against highly validated but inadequately drugged targets. Their focus is on tackling immunological and orphan diseases, aiming to improve the lives of patients with these conditions. OMass leverages a proprietary platform that combines novel biochemistry techniques, native mass spectrometry, and custom chemistry to interrogate target ecosystems in their native state. This approach allows them to understand the complex interactions of proteins and their environment, leading to the identification of drug candidates with better efficacy and specificity.

OMass Therapeutics is well-funded, backed by a top-tier investor syndicate including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, and British Patient Capital. They are rapidly growing their team of scientists and researchers, aiming to build a fully integrated biopharma company that can bring its own products to market. With a focus on cutting-edge technology and a commitment to innovation, OMass is poised to become a leader in the fight against challenging diseases.

OMass Therapeutics offers a hybrid working model, which allows employees to work both from their home and their office location. This flexibility provides employees with the ability to manage their work-life balance and create a working environment that suits their individual needs.

OMass Therapeutics provides a comprehensive benefits package that includes private health care, a cycle to work scheme, life assurance, income protection with 24/7 access to advice, and a company pension. In addition to these standard benefits, they offer hybrid working arrangements and a competitive remuneration package. OMass also emphasizes the importance of personalized support and a strong company culture, which allows employees to receive tailored help and feel connected to the team.

OMass Therapeutics is a biotechnology company developing novel small molecule drugs against membrane proteins and intracellular complexes, particularly targeting immunological and orphan diseases. Their proprietary OdyssION™ platform leverages native mass spectrometry and other biophysical approaches to precisely interrogate the physical interactions within a target's native ecosystem, enabling the discovery of new drugs against historically difficult targets. Their ultimate goal is to improve the lives of patients suffering from these often neglected diseases.

OMass Therapeutics cultivates a collaborative and supportive culture where employees are encouraged to be innovative and push boundaries. The company emphasizes a strong work ethic while valuing individual contributions and fostering a sense of belonging. This inclusive environment promotes diversity and celebrates the achievements of its team, creating a positive and rewarding workplace.

OMass Therapeutics is committed to building a diverse and inclusive culture where everyone feels welcome and opportunity is equal. They proactively educate themselves and each other about how to be more inclusive and work to remove bias from their processes. They celebrate the diversity they already have, with no single gender dominating and employees representing over 20 countries of origin. Their commitment to diversity, equity, and inclusion is part of their company values and a core element of their people strategy.